e-learning
resources
Virtual 2020
Pre-Congress Content
Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Feasibility of microRNA signatures for detection early stage pulmonary hypertension
A. Waxman (Boston, United States of America), Y. Fong (Raritan, United States of America), T. Jatkoe (Raritan, United States of America), H. Cheng (Singapore, Singapore), L. Zhou (Singapore, Singapore), C. Bridges (Boston , United States of America)
Source:
Virtual Congress 2020 – Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension
Session:
Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension
Session type:
E-poster session
Number:
1532
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Waxman (Boston, United States of America), Y. Fong (Raritan, United States of America), T. Jatkoe (Raritan, United States of America), H. Cheng (Singapore, Singapore), L. Zhou (Singapore, Singapore), C. Bridges (Boston , United States of America). Feasibility of microRNA signatures for detection early stage pulmonary hypertension. 1532
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on acute decompensated pulmonary hypertension
The definition of pulmonary hypertension: history, practical implications and current controversies
Pathophysiology of central apnoea: how do we distinguish normal from abnormal?
Related content which might interest you:
Proteomic profiling identifies an exercise signature in patients with pulmonary arterial hypertension
Source: Virtual Congress 2020 – Exercise and haemodynamics in pulmonary hypertension
Year: 2020
Towards early detection of pulmonary hypertension: a call to arms
Source: Eur Respir J 2014; 43: 16-19
Year: 2004
Proof of concept of a non-invasive screening tool to detect idiopathic pulmonary fibrosis (IPF) in an early stage
Source: International Congress 2018 – What is new in idiopathic interstitial pneumonias?
Year: 2018
Identifying early pulmonary arterial hypertension biomarkers in systemic sclerosis: machine learning on proteomics from the DETECT cohort
Source: Eur Respir J, 57 (6) 2002591; 10.1183/13993003.02591-2020
Year: 2021
CIPHER: a prospective, multicentre study for the identification of biomarker signatures for early detection of pulmonary hypertension
Source: Virtual Congress 2020 – Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension
Year: 2020
Systematic cardiac echoscreening is effective in detecting early stage pulmonary arterial hypertension in systemic sclerosis
Source: Annual Congress 2004 - Pulmonary hypertension
Year: 2004
Evaluating the effects of pulmonary rehabilitation in patients with COPD in early and late disease stages.
Source: Annual Congress 2008 - Impact of rehabilitation programmes in COPD and non-COPD patients
Year: 2008
Improving identification and early referral of pulmonary hypertension patients
Source: International Congress 2016 – Pulmonary hypertension: the clinic II
Year: 2016
Issues other than tissue: non-invasive biomarkers of early stage lung cancer
Source: Virtual Congress 2020 – Will the pulmonologist still play a role in the management of screen-detected pulmonary nodules?
Year: 2020
Early detection and management of pulmonary arterial hypertension
Source: Eur Respir Rev 2012 21: 306-312
Year: 2012
Evaluation of recently validated non-invasive formula using basic lung functions as a new screening tool for pulmonary hypertension in patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2009 - Pulmonary vascular diseases
Year: 2009
A novel whole-blood miRNA signature for a rapid diagnosis of pulmonary tuberculosis
Source: Eur Respir J 2015; 45: 1173-1176
Year: 2015
Differential expression of plasma microRNAs in chronic thromboembolic pulmonary hypertension and pulmonary embolism related to occult cancer
Source: Virtual Congress 2021 – Pathogenesis and pathophysiology of pulmonary hypertension
Year: 2021
Analysis of miRNA profile in circulating microparticles of patients with pulmonary arterial hypertension
Source: International Congress 2015 – Pulmonary hypertension: rare and hereditary causes of PAH
Year: 2015
Screening for and early detection of COPD: feasibility and impact
Source: Annual Congress 2009 - LANCET/ERS symposium: “Evolving dimensions of COPD”
Year: 2009
Screening for biomarkers in pulmonary hypertension
Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and cell biology
Year: 2012
Identification of novel diagnostic biomarkers of chronic thromboembolic pulmonary hypertension using MALDI-TOF-MS
Source: Annual Congress 2010 - Pulmonary hypertension
Year: 2010
How to detect disease progression in pulmonary arterial hypertension
Source: Eur Respir Rev 2012; 21: 40-47
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept